Development of small molecules to target KDM4B
开发针对 KDM4B 的小分子
基本信息
- 批准号:9580417
- 负责人:
- 金额:$ 41.06万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-07-01 至 2022-06-30
- 项目状态:已结题
- 来源:
- 关键词:Acute Myelocytic LeukemiaBinding SitesBiochemicalBiologicalBiological AssayBiological ProcessBiological SciencesBiologyBiophysicsBreast Cancer CellCalorimetryCancer ModelCatalytic DomainCell Cycle ProgressionCellsCellular biologyChemicalsClinical TrialsCollectionDevelopmentDiseaseDisease modelDoseDrug KineticsEnsureEnzymesEpigenetic ProcessEstrogen Receptor alphaFamilyFamily memberFluorescence Resonance Energy TransferFusion Oncogene ProteinsFutureGene ExpressionGenetic TranscriptionGoalsGrowthHistonesHypoxiaImageImmunofluorescence ImmunologicIn VitroInstitutionLaboratoriesLeadLibrariesLysineMLL-AF9Malignant Childhood NeoplasmMalignant NeoplasmsMalignant neoplasm of prostateMass Spectrum AnalysisMethylationMolecularNeoplasm MetastasisNeuroblastomaOncogenicOncoproteinsPathogenicityPathway interactionsPharmaceutical ChemistryPhenotypePlayPre-Clinical ModelProtein IsoformsProteinsPublishingResearch PersonnelResource SharingResourcesRoleSaint Jude Children&aposs Research HospitalSpecificityStem cellsStructureSubstrate SpecificitySupport GroupsSurface Plasmon ResonanceTestingTherapeuticTimeTitrationsTranslatingTreatment EfficacyValidationX-Ray CrystallographyYangZoranassay developmentbasebiophysical analysiscancer cellcancer initiationcancer therapycheminformaticsdrug discoverygenome integritygroup supporthigh throughput screeninghistone demethylasehistone methyltransferasehistone modificationhypoxia inducible factor 1in vivoinhibitor/antagonistmalignant breast neoplasmmembernovelpre-clinicalprogramsrecruitresponsescreeningsmall moleculestructural biologytargeted cancer therapytherapeutic developmenttherapeutic targettooltranscription factortumor progressiontumorigenesis
项目摘要
ABSTRACT
Epigenetic modifications of histone proteins play key roles in regulating transcription, and dysregulation
of the epigenetic machinery has emerged as important driver of cancer initiation and progression. Histone
lysine methylation is an important epigenetic mark that is dynamically regulated by histone methyltransferase
`writers' and histone lysine demethylase `erasers' (KDMs). The KDMs comprise two structurally and
mechanistically distinct classes of enzymes, and there is firm evidence that KDM4B in the larger Jumonji C
(JmjC) class has a particularly key role in several cancers including breast and prostate cancer, acute myeloid
leukemia and neuroblastoma. Published and ongoing studies from our group support the importance of
KDM4B in breast cancer and neuroblastoma. These results have prompted us to initiate screening, cell
biology and structural biology efforts to identify specific inhibitors of KDM4B. Two key findings from our studies
provide a proof-of-concept that targeting KDM4B is a potentially valuable therapeutic option in cancer
treatment. First, N-Myc recruits KDM4B to maintain low levels of repressive H3K9me2/me3 at Myc-binding
sites and promotes neuroblastoma growth. Second, the small molecule ciclopirox inhibits KDM4B activity,
suppresses the N-Myc pathway and reduces neuroblastoma growth.
The immediate goal of this proposal within the scope of this FOA is to develop novel and potent
inhibitors of KDM4B that display specificity within the JmjC class of KDMs. Such inhibitors can then be used to
develop competent in vivo chemical probes to study the roles of KDM4B and other members of the KDM family
in relevant preclinical cancer models. A longer term goal is to develop small molecule cancer therapies that
target KDM4B. Previous biochemical and structural biology studies have thoroughly characterized the catalytic
mechanism and substrate specificities of these enzymes, and this information will fully exploited as we
proceed. Four laboratories with diverse expertise have and will continue to collaborate on this project: Drs. Jun
Yang and Andrew Davidoff (hit validation), Dr. Taosheng Chen (screening), and Dr. Stephen White
(biophysical studies and structural biology). In addition, Dr. Zoran Rankovic will provide medicinal chemistry
expertise that will be increasingly important as we move towards therapeutic development. As defined within
the FOA, the project includes 3 stages: assay development (Stage 1), primary screen implementation (Stage
2) and hit validation (Stage 3). Stages 1 and 2 are well advanced and the emphasis will therefore be on Stage
3.
摘要
组蛋白的表观遗传修饰在调节转录和失调中起关键作用
表观遗传机制已经成为癌症发生和发展的重要驱动力。组蛋白
赖氨酸甲基化是一种重要的表观遗传标记,受组蛋白甲基转移酶的动态调节
“写入器”和组蛋白赖氨酸脱甲基酶“擦除器”(KDM)。KDM在结构上包括两个,
机械上不同类别的酶,有确凿的证据表明,KDM 4 B在较大的Jumonji C
(JmjC)类在包括乳腺癌和前列腺癌、急性骨髓性白血病和骨髓性白血病在内的几种癌症中具有特别关键的作用。
白血病和神经母细胞瘤。我们小组已发表和正在进行的研究支持以下重要性:
乳腺癌和神经母细胞瘤中的KDM 4 B。这些结果促使我们开始筛选,细胞
生物学和结构生物学的努力,以确定KDM 4 B的特异性抑制剂。我们研究的两个关键发现
提供了一个概念验证,靶向KDM 4 B是一种潜在的有价值的癌症治疗选择
治疗首先,N-Myc募集KDM 4 B以在Myc结合时维持低水平的抑制性H3 K9 me 2/me 3。
并促进神经母细胞瘤的生长。其次,小分子环吡酮抑制KDM 4 B活性,
抑制N-Myc通路并减少神经母细胞瘤生长。
在本FOA范围内,该提案的直接目标是开发新颖而有效的
KDM 4 B的抑制剂,其在KDM的JmjC类内显示特异性。这样的抑制剂然后可以用于
开发合适的体内化学探针,以研究KDM 4 B和KDM家族其他成员的作用
在相关的临床前癌症模型中。更长期的目标是开发小分子癌症疗法,
目标是KDM 4 B以前的生物化学和结构生物学研究已经彻底表征了催化
这些酶的机制和底物特异性,这些信息将充分利用,因为我们
继续.四个拥有不同专业知识的实验室已经并将继续在这个项目上合作:
Yang和Andrew Davison(命中验证)、Dr. Taosheng Chen(筛选)和Dr. Stephen白色
(生物物理学和结构生物学)。此外,佐兰·兰科维奇博士将提供药物化学
随着我们向治疗发展,这些专业知识将变得越来越重要。内定义的
根据FOA,该项目包括3个阶段:检测开发(第1阶段)、初步筛选实施(第
2)和命中验证(阶段3)。第一阶段和第二阶段已经很深入,因此重点将放在第二阶段
3.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Taosheng Chen其他文献
Taosheng Chen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Taosheng Chen', 18)}}的其他基金
Development of small molecules to target KDM4B
开发针对 KDM4B 的小分子
- 批准号:
10188460 - 财政年份:2018
- 资助金额:
$ 41.06万 - 项目类别:
Regulation of xenobiotic receptors PXR and CAR: implications in drug disposition
外源性受体 PXR 和 CAR 的调节:对药物处置的影响
- 批准号:
9889965 - 财政年份:2016
- 资助金额:
$ 41.06万 - 项目类别:
Regulation of xenobiotic receptors PXR and CAR, and CYP3A: implications in drug disposition
外源性受体 PXR 和 CAR 以及 CYP3A 的调节:对药物处置的影响
- 批准号:
10391535 - 财政年份:2016
- 资助金额:
$ 41.06万 - 项目类别:
Regulation of xenobiotic receptors PXR and CAR, and CYP3A: implications in drug disposition
外源性受体 PXR 和 CAR 以及 CYP3A 的调节:对药物处置的影响
- 批准号:
10206725 - 财政年份:2016
- 资助金额:
$ 41.06万 - 项目类别:
Regulation of xenobiotic receptors PXR and CAR: implications in drug disposition
外源性受体 PXR 和 CAR 的调节:对药物处置的影响
- 批准号:
9516642 - 财政年份:2016
- 资助金额:
$ 41.06万 - 项目类别:
Regulation of xenobiotic receptors PXR and CAR, and CYP3A: implications in drug disposition
外源性受体 PXR 和 CAR 以及 CYP3A 的调节:对药物处置的影响
- 批准号:
10595631 - 财政年份:2016
- 资助金额:
$ 41.06万 - 项目类别:
Regulation of drug disposition by a novel microRNA-mediated pathway
通过新型 microRNA 介导的途径调节药物分布
- 批准号:
9005869 - 财政年份:2014
- 资助金额:
$ 41.06万 - 项目类别:
Regulation of drug disposition by a novel microRNA-mediated pathway
通过新型 microRNA 介导的途径调节药物分布
- 批准号:
8670437 - 财政年份:2014
- 资助金额:
$ 41.06万 - 项目类别:
相似海外基金
BIOCHEMICAL CHARACTERIZATION OF OPIOID BINDING SITES
阿片类药物结合位点的生化特征
- 批准号:
3207446 - 财政年份:1980
- 资助金额:
$ 41.06万 - 项目类别:
BIOCHEMICAL CHARACTERIZATION OF OPIOID BINDING SITES
阿片类药物结合位点的生化特征
- 批准号:
2116613 - 财政年份:1980
- 资助金额:
$ 41.06万 - 项目类别:
BIOCHEMICAL CHARACTERIZATION OF OPIATE BINDING SITES
阿片结合位点的生化特征
- 批准号:
3207448 - 财政年份:1980
- 资助金额:
$ 41.06万 - 项目类别:
BIOCHEMICAL CHARACTERIZATION OF OPIATE BINDING SITES
阿片结合位点的生化特征
- 批准号:
3207451 - 财政年份:1980
- 资助金额:
$ 41.06万 - 项目类别:
BIOCHEMICAL CHARACTERIZATION OF OPIOID BINDING SITES
阿片类药物结合位点的生化特征
- 批准号:
6515354 - 财政年份:1980
- 资助金额:
$ 41.06万 - 项目类别:
BIOCHEMICAL CHARACTERIZATION OF OPIOID BINDING SITES
阿片类药物结合位点的生化特征
- 批准号:
6730581 - 财政年份:1980
- 资助金额:
$ 41.06万 - 项目类别:
Biochemical Characterization of Opioid BInding Sites
阿片类药物结合位点的生化特征
- 批准号:
8422976 - 财政年份:1980
- 资助金额:
$ 41.06万 - 项目类别:
BIOCHEMICAL CHARACTERIZATION OF OPIOID BINDING SITES
阿片类药物结合位点的生化特征
- 批准号:
6634154 - 财政年份:1980
- 资助金额:
$ 41.06万 - 项目类别:
BIOCHEMICAL CHARACTERIZATION OF OPIATE BINDING SITES
阿片结合位点的生化特征
- 批准号:
3207444 - 财政年份:1980
- 资助金额:
$ 41.06万 - 项目类别:
BIOCHEMICAL CHARACTERIZATION OF OPIATE BINDING SITES
阿片结合位点的生化特征
- 批准号:
3207450 - 财政年份:1980
- 资助金额:
$ 41.06万 - 项目类别: